Because SerpinF2 reduces fibrinolysis by inhibiting plasmin, this suggests that there may be increased fibrinolytic activity in patients with heart failure; however, how/if this relates to the relative risks of bleeding versus thrombosis in heart failure remains to be investigated. The gene discussed is SERPINF2; the disease is heart failure.